In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Report 2026

In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Overview

• In Vitro Diagnostic (IVD) In Cardiology And Neurology market size has reached to $17.22 billion in 2025 • Expected to grow to $25.18 billion in 2030 at a compound annual growth rate (CAGR) of 7.7% • Growth Driver: Impact Of Personalized Medicine On The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market • Market Trend: Advancing Diagnostics Through Innovations In AI-Enabled Early Disease Detection • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

In vitro diagnostic (IVD) in cardiology and neurology refers to medical tests performed on samples such as blood, urine, or tissue outside the body to diagnose various cardiovascular and neurological conditions. These tests play a crucial role in early detection, monitoring, and treatment decisions for diseases such as heart disease, stroke, Alzheimer's disease, and others. It also provides timely diagnostic information, guiding patient management, and improving outcomes in cardiology and neurology. The main products of in vitro diagnostic (IVD) in cardiology and neurology are instruments, reagents and consumables, and software and services. Instruments refer to devices or equipment used for performing diagnostic tests and analyzing patient samples in laboratory settings. The various technologies involved are immunoassays, molecular diagnostics, hematology, and others used by hospitals, clinical laboratories, and others.

What Is The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Growth Forecast?

The in vitro diagnostic (ivd) in cardiology and neurology market size is expected to see strong growth in the next few years. It will grow to $25.18 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to aging global population, rising demand for personalized diagnostics, expansion of point-of-care testing facilities, increasing healthcare expenditure in emerging markets, growing adoption of molecular diagnostics. Major trends in the forecast period include rising demand for early disease detection, increasing adoption of point-of-care cardiac and neuro tests, expansion of biomarker-based diagnostics, growing focus on preventive and predictive testing, integration of multi-parameter diagnostic panels.

Global In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Segmentation

1) By Product Type: Instruments, Reagents And Consumables, Software And Services 2) By Technology: Immunoassays, Molecular Diagnostics, Hematology, Other Technologies 3) By End-User: Hospitals, Clinical Laboratories, Other End-Users Subsegments: 1) By Instruments: Diagnostic Analyzers, Point-Of-Care Devices 2) By Reagents And Consumables: Diagnostic Reagents, Test Kits, Assay Consumables 3) By Software And Services: Diagnostic Software, Data Management Software, IVD Consulting And Support Services

What Is The Driver Of The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

The expansion of personalized medicine is expected to fuel the growth of the in vitro diagnostic (IVD) in cardiology and neurology market going forward. Personalized medicine refers to a medical approach that tailors healthcare decisions, practices, interventions, and treatments to individual characteristics of each patient. Personalized medicine is expanding due to advancements in genomics, increased understanding of disease mechanisms, patient demand for tailored treatments, and regulatory support, among other factors. In vitro diagnostic (IVD) tests in cardiology and neurology facilitate personalized medicine by providing crucial information about an individual's genetic makeup and disease status, guiding tailored treatment plans for improved efficacy and reduced risks. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit research organization, the U.S. Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, up from six approvals in 2022, with the 2023 approvals also encompassing seven oncology therapies and three treatments targeting various other conditions. Therefore, the increasing number of personalized medicines is driving the growth of the in vitro diagnostic (IVD) in cardiology and neurology industry.

Key Players In The Global In Vitro Diagnostic (IVD) In Cardiology And Neurology Market

Major companies operating in the in vitro diagnostic (ivd) in cardiology and neurology market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson And Company, Quest Diagnostics Incorporated, Hologic Inc., Illumina Inc., Beckman Coulter Inc., Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Instrumentation Laboratory, bioMérieux SA, Natera, Inc., Randox Laboratories Ltd., Fulgent Genetics Inc., DiaSorin S.p.A., Oxford Nanopore Technologies, Fujirebio Diagnostics Inc., Adaptive Biotechnologies, Biocartis Group NV, Agena Bioscience

Global In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Trends and Insights

Major companies operating in the in vitro diagnostic (IVD) in cardiology and neurology market are developing AI-enabled integrated epigenetic engines for early disease detection and risk assessment. AI-enabled integrated epigenetic engines leverage machine-learning models and advanced biomarker analysis techniques to enhance sensitivity and accuracy in diagnosing and monitoring cardiovascular diseases, addressing critical drivers of disease progression. For instance, in February 2023, Cardio Diagnostics Holdings Inc., a US-based biotechnology company, launched PrecisionCHD, an AI-based blood test, designed for the early detection of coronary heart disease (CHD). Utilizing the company's integrated epigenetic-genetic engine, this test evaluates CHD risk and aims to prevent and detect the most common form of cardiovascular disease. The new test combines epigenetic and genetic biomarkers with machine-learning algorithms, offering over 75% sensitivity for both men and women. It links a patient's biomarker profile to modifiable risk factors, major contributors to CHD, like smoking, diabetes, hypertension, and high cholesterol. PrecisionCHD represents a non-invasive alternative to exercise stress tests or angiograms, with blood samples drawn in-office or at home.

What Are Latest Mergers And Acquisitions In The In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

In March 2024, Beckman Coulter, a US-based company that offers laboratory diagnostics, expanded its partnership with Fujirebio focused on the development, manufacturing, and clinical adoption of neurodegenerative disease assays. With this partnership, Beckman Coulter and Fujirebio aim to leverage their combined expertise in laboratory diagnostics and neurological markers to enhance the development, manufacturing, and clinical adoption of innovative assays for diagnosing neurodegenerative diseases, ultimately improving patient outcomes through more accurate and timely diagnostics. Fujirebio is a Japan-based company that offers n vitro diagnostic (IVD) in cardiology and neurology.

Regional Outlook

North America was the largest region in the in vitro diagnostic (IVD) in cardiology and neurology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market?

The in vitro diagnostic (IVD) in cardiology and neurology market consists of revenues earned by entities by providing services such as laboratory testing, point-of-care testing, molecular diagnostics, and biomarker testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The in vitro diagnostic (IVD) in cardiology and neurology market also includes sales of laboratory testing, point-of-care testing, molecular diagnostics, and biomarker testing. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the In Vitro Diagnostic (IVD) In Cardiology And Neurology Market Report 2026?

The in vitro diagnostic (ivd) in cardiology and neurology market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the in vitro diagnostic (ivd) in cardiology and neurology industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.